HRSA Will Still Fine Drug Makers Despite Revoking 340B Advisory Opinion

By Gabrielle Wanneh / June 22, 2021 at 3:09 PM
HHS told a federal court it will proceed with fines against pharmaceutical makers that restrict 340B discounts for drugs dispensed via contract pharmacies, even though the department scrapped a controversial advisory opinion on the issue. 340B Health praised HHS’ pledge to continue enforcement, but the brand drug lobby said the administration shouldn’t allow for-profit pharmacies and other middlemen to participate in the safety-net program. At issue is the Health Resources and Services Administration’s effort to fine drug makers that cut...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.